Phase 2
Completed N=203
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
Source: ClinicalTrials.gov NCT01361568 ↗Enrolled (actual)
203
Serious AEs
6.4%
Results posted
May 2014
Primary outcomePrimary: Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment — 21.9; 17.6; 13.9; 19.8 mg — p=<0.05
Summary
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment |
21.9; 17.6; 13.9; 19.8 | <0.05 sig |
| SECONDARY Summed Pain Intensity Difference From 0-24 Hours (SPID 0-24) Following Postoperative Study Drug Treatment Using Last Observation Carried Forward (LOCF) |
-413.1; -643.2; -833.1; -673.5 | <0.01 sig |
| SECONDARY Morphine Consumption Following Postoperative Study Drug Treatment in the 2-24 Hour Period After Recovery in the Post-Anesthesia Care Unit (Post-PACU) |
14.38; 11.07; 7.99; 11.33 | <0.05 sig |
| SECONDARY Total Pain Relief Within the First 2 Hours (TOTPAR 0-2) Following Postoperative Study Drug Treatment Using LOCF |
1.4; 2.1; 2.4; 1.5 | <0.05 sig |
| SECONDARY Global Evaluation Responder Analysis |
27; 68 | 0.001 sig |
| SECONDARY Total Number of Patients Reporting At Least One Episode of Nausea |
51.2; 26.1 | <0.001 sig |
| SECONDARY Total Number of Patients Reporting At Least One Episode of Vomiting |
8.3; 1.7 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Able to provide written informed consent prior to any study procedures;
- Able to communicate clearly with the Investigator and staff;
- Female between 21 and 65 years of age, inclusive;
- Scheduled for elective laparoscopic hysterectomy under general anesthesia;
- Negative result on serum pregnancy test at screening and negative urine pregnancy test at Baseline (for women of child-bearing potential only) and not currently breast feeding, or planning to do so within 30 days of dosing;
- Negative urine drug screen for drugs of abuse at Screening and at Baseline;
- American Society of Anesthesiologists (ASA) risk class of I to III;
- Body mass index (BMI) between 17 and 40 inclusive.
Exclusion Criteria
- Has known allergies to opioids, or hypersensitivity to other materials (such as infusion line) or medications to be used in the study;
- Has a known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-diagnosed alcohol, opiate or other drug abuse or dependence within 12 months prior to screening;
- Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the Treatment Period;
- Is scheduled to undergo a hysterectomy that will utilize any type of robotic technology and/or a concomitant surgical procedure that would produce a significantly greater degree of surgical trauma than the laparoscopic hysterectomy or laparoscopic assisted vaginal hysterectomy alone;
- Has taken non-opioid analgesics (including cyclooxygenase-2 [COX-2] inhibitors) or nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 hours of the Baseline assessments;
- Has taken any opioid analgesics or used systemic steroids within 4 days of surgery OR has previously used opiates chronically for a period of ≥3 months;
- Has used antipsychotics, antiepileptics, sedatives, hypnotics, or antianxiety agents, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants for 2.5 x the upper limit of normal (ULN) at screening;
- Has bilirubin, blood urea nitrogen (BUN), or creatinine >1.5 x the reference ULN at Screening;
- Has abnormally low hemoglobin 146 mmol/L at Screening;
- Has impaired renal function (creatinine clearance [CrCl] < 50 ml/min) at Screening;
- Has a positive test for human immunodeficiency virus (HIV) or known history of HIV infection;
- Has received another investigational drug within 30 days of scheduled surgery;
- Has a significant chronic pain condition in areas unrelated to the operative site at the time of Screening that in the Investigator's opinion could confound the interpretation of study results
Data sourced from ClinicalTrials.gov (NCT01361568). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.